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1. Introduction 
Sepsis is the leading cause of death in most intensive care units (Angus et al., 2001; Martin et 
al., 2003). Sepsis results from dysregulation of the normally protective anti-microbial host 
defense mechanism and represents a systemic inflammatory response that is associated with 
hypotension, insufficient tissue perfusion, uncontrolled bleeding, and multiple organ 
failure/dysfunction (Bone et al., 1992; Natanson et al., 1994). Accordingly, a major focus of 
sepsis research has been the development of anti-inflammatory strategies. In clinical trials, 
however, most of the therapies that may modify systemic inflammation have largely failed 
to reduce mortality in patients with severe sepsis (Zeni et al., 1997; Natanson et al., 1998; 
Marshall, 2000). These failed trials include administration of high-dose glucocorticoids; 
polyclonal and monoclonal antibodies against endotoxin and various inflammatory 
mediators such as tumor necrosis factor (TNF)-; anti-inflammatories; nitric oxide (NO) 
inhibitors; anti-oxidants; and others. Hence, new understanding of the pathophysiological 
mechanisms underlying this complex disorder is needed to develop novel therapeutic 
strategies that will impact favorably on septic patient outcome. 
Apoptosis is a second prominent feature of sepsis. This process is a mechanism of tightly 
regulated disassembly of cells caused by activation of certain specialized proteases called 
caspases. A number of laboratories have demonstrated that sepsis induces extensive 
lymphocyte apoptosis, which can impairment of immunoresponses, thereby predisposing 
patients to septic death (Ayala & Chaudry, 1996; Wesche et al., 2005; Hotchkiss et al., 2005; 
Lang & Matute-Bello, 2009; Matsuda et al., 2010a). Parenchymal cells, including intestinal 
and lung epithelial cells, also have increased apoptotic cell death in animal models of sepsis 
(Coopersmith et al., 2002a, 2002b; Perl et al., 2007). An autopsy study comparing samples 
from multiple organ systems in 20 patients who died of sepsis with those from 16 critically 
ill, non-septic patients has shown that gut epithelial apoptosis is increased in septic patients 
(Hotchkiss et al., 1999a). Moreover, it has been suggested that vascular endothelial cells may 
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be undergoing apoptosis in sepsis (Hotchkiss et al., 2002). In sepsis, endothelial cell 
apoptosis may be associated with microvascular dysfunction with reduced perfusion and 
oxygen, which could result in tissue hypoxia and, ultimately, in the development of organ 
failure (Matsuda & Hattori, 2007). This could explain partly the disappointment in a large 
number of sepsis trials conducted with interventions against individual steps in the 
inflammatory cascade, leading investigators to the question of whether death in septic 
patients stems from uncontrolled inflammation (Hattori et al., 2010). 
To reduce sepsis-induced apoptosis, caspase inhibitors have been examined in mice with 
cecal ligation and puncture (CLP)-induced sepsis. It has been reported that the pan-caspase 
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp (O-methyl) fluoromethyl ketone (z-VAD) 
decreases lymphocyte apoptosis in the thymus and spleen, decreases blood bacterial counts, 
and improves survival in sepsis (Hotchkiss et al., 1999b). In a similar study, the pan-caspase 
inhibitor L-826,920 (M-920) and the selective caspase-3 inhibitor L-826,791 (M-791) have 
shown a survival benefit being the result of the rescue of lymphocytes from apoptosis 
(Hotchkiss et al., 2000). Furthermore, Kawasaki et al. (2000) have demonstrated that z-VAD 
decreases apoptosis on pulmonary endothelial cells and epithelial cells and prolongs the 
survival rate in a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model. 
However, successful anti-apoptotic therapy in sepsis with caspase inhibitors may be 
challenging, because caspase inhibitors themselves can have detrimental effects within the 
cell when large amounts of them must reach the cell cytosol to inhibit apoptosis that is 
initiated only by small amounts of caspases. In fact, survival in z-VAD high-dose group after 
CLP returns toward the level of the control (Hotchkiss et al., 1999b), indicating that there 
appears to be close-limiting toxicity associated with the administration of z-VAD. 
Small interfering RNA (siRNA) is another potential reversible inhibitor of the apoptotic 
death pathways. siRNA therapy may offer a unique alternative sepsis treatment to shorten 
the apoptotic arm of sepsis, revealing a number of targets within the apoptotic death 
pathways, which may be useful in designing stand-alone and/or adjuvant therapies that 
would have a significant impact on septic mortality. Although the causative agents of sepsis 
vary widely as do their traditional anti-microbial treatments, siRNA therapy targeted 
toward salvaging immune effector cells, vascular endothelial cells, and parenchymal cells 
from apoptosis has the potential to be beneficial in sepsis regardless of the source. We have 
generated synthetic double-stranded siRNA targeting Fas-associated death domain (FADD) 
and examined the therapeutic effect of systemic administration of the siRNA in the CLP 
mouse model, regarded as a highly clinically relevant animal model of polymicrobial sepsis. 
As described below, FADD is an essential component of the death-inducing signaling 
complex (DISC) for all death receptors (Thorburn, 2004; Lavrik et al., 2005). Here we present 
that this RNA interference-mediated gene silencing in vivo is effective as gene therapy of the 
septic syndrome. 
2. Apoptotic cell death pathways 
Two major pathways are involved in the initiation of apoptotic cell death (Figure 1) (Roy & 
Nicholson, 2000). The first apoptotic pathway is mediated by specific ligands and surface 
receptors, which are capable of delivering a death signal from the microenvironment and 
can activate the execution of apoptosis in the cell cytoplasm and organelles (Herr & Debatin,  
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The extrinsic, death receptor-mediated apoptotic pathway involves the binding of TNF- or FasL to its 
cell surface receptor, resulting in the activation of caspase-8 and, subsequently, caspase-3. FADD serves 
as a docking protein for caspase-8, tethering the enzyme to activated death receptor. The intrinsic, 
mitochondria-mediated apoptotic pathway results in the release of cytochrome c, which binds to APAF-
1 and caspase-9, thus forming the apoptosome. This complex activates caspase-3, which is involved in 
the final common pathway of the cell death program. The interaction of these two cell death pathways 
via tBID are presented. 
Fig. 1. Two major pathways involved in initiation of apoptosis. 
2001). This pathway is termed the extrinsic pathway. The second apoptotic pathway called 
the intrinsic pathway is activated by mitochondrial injury (Korsmeyer, 1999). The two 
apoptotic signaling pathways ultimately converge into a common pathway causing the 
activation of effector enzymes termed caspases. 
The extrinsic pathway involves activation of members of the TNF receptor (TNF-R) family 
with an intracellular death domain (DD), including TNF-R1, Fas, DR3, DR4, DR5, and DR6. 
These death receptors transmit apoptotic signals initiated by specific ligands such as TNF-, 
Fas ligand (FasL), and TRAIL. Thus, once activated, death receptors recruit the adaptor 
molecule FADD (plus others in some cases) through the homophilic interaction of their own 
DD to the DD of the adaptor molecule. FADD can then recruit the apoptosis initiator 
enzyme procaspase-8 into the DISC as a consequence of the death effector domain-mediated 
homophilic interaction. Subsequently, procaspase-8 is activated proteolytically into caspase-
8 and further activates the apoptosis effector enzymes caspase-3 and other execuitioner 
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caspases (caspase-6 and caspase-7) (Thorburn, 2004; Lavrik et al., 2005; Green & Kroemer, 
2005). 
The intrinsic pathway is initiated by stress signals through the release of apoptogenic factors 
such as cytochrome c from the mitochondrial intermembrane space. Upon release into the 
cell cytoplasm, cytochrome c promotes the formation of a complex between the caspase 
adaptor molecule APAF-1 and the apoptosis initiator enzyme termed procaspase-9 in a 
caspase-activating structure known as the apoptosome, and consequently triggers the 
apoptotic cascade by activating procaspase-9. Thus, the apoptosome, through newly 
activated caspase-9, activates the effector caspases along the common pathway of apoptosis 
(Korsmeyer, 1999). 
In certain types of cells, there is extensive cross-talk that occurs between the extrinsic and 
intrinsic apoptotic pathways (Roy & Nicholson, 2000). Thus, the extrinsic and intrinsic 
apoptotic pathways are intimately connected. This appears to occur via the proteolysis of 
BID, which normally serves an anti-apoptotic role within the intrinsic mitochondrial-
mediated pathway. BID is truncated to receptor pathway, whereupon tBID promotes 
activation of Bax and Bak and thereby induces cytochrome c release, leading to formation of 
the apoptosome (Esposti, 2002). 
3. Impact of the FADD gene silencing with siRNA in sepsis therapy 
3.1 Sepsis-induced up-regulation of death receptors 
We initially verified the hypothesis that tissue expression of death receptors is up-regulated 
in sepsis. Polymicrobial sepsis was induced by CLP in BALB/c mice (Matsuda et al., 2005). A 
middle abdominal incision was performed under anesthesia. The cecum was mobilized, 
ligated at 5 mm from its top, and then perforated in two locations with a 21-gauge needle, 
allowing expression of feces. The bowel was repositioned, and the abdomen was closed. 
Sham-operated animals underwent the same procedure except for ligation and puncture of 
the cecum. This model has high clinical relevance to humans, because it reproduces many 
hallmarks of sepsis that occur in patients (Hubbard et al., 2005). 
Immunoblot analysis showed that surface expression of the two death receptors TNF-R1 
and Fas were up-regulated in lung tissues with time after CLP induction of sepsis (Figure 
2A). Immunohistochemical studies indicated more abundant TNF-R1 expression in the 
inner wall of microvessels from septic mouse lungs (Figure 2B). Meanwhile, Fas was 
detected mainly in alveolar epithelial Type II cells (Matsuda et al., 2009). Similar to these 
death receptors, DR4 and DR5, both of which mediate TRAIL-induced cell death, were up-
regulated in septic mouse lungs (Matsuda et al., 2009). We also found time-dependent 
increases in surface expression of TNF-R1 and Fas in mouse aortic tissues after CLP sepsis 
(Figure 3A). These death receptors are likely to be up-regulated mainly on endothelial cells, 
because the sepsis-induced up-regulation of TNF-R1 and Fas expression in aortic tissues 
was abolished when the tissues were denuded mechanically. Previous works from other 
laboratory have demonstrated that Fas expression is increased in hepatocytes and in 
selected gastrointestinal-associated lymphoid tissues (Chung et al., 2001, 2003). Moreover, 
splenocytes harvested 24 hours after CLP and stimulated with the T cell mitogen concavalin 
A showed an increase in CD4+ T-cell apoptosis as compared to sham controls, which was 
associated with an increase in Fas expression (Ayala et al., 1999). Based on the findings of  
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(A) Western blots of TNF-R1 and Fas in the membrane fractions of lung tissues from mice that were 
subjected to sham operation (control) and sepsis (10 and 24 hours after CLP). Adaptin- served as 
loading control. (B) Immunohistochemical finding for TNF-R1 in the lung section from the mouse 
subjected to sepsis (24 hours after CLP). Positive staining is indicated by arrows. 
Fig. 2. Increased death receptor expression in lung tissues of septic mice. 
increased death receptor expression in tissues of septic mice, we suggest the importance of 
the extrinsic death receptor pathway in apoptotic cell death in sepsis, although a preeminent 
role for the intrinsic mitochondrial pathway has often been noted (Exline & Crouser, 2008). 
As presented in Figure 1, death receptors, after ligand binding, recruit the adaptor protein 
FADD through hemophilic interaction of their DD with the DD of FADD, and then FADD 
can recruit procaspase-8 to the DISC, thereby causing its activation (Thorburn, 2004; Lavrik 
et al., 2005). When FADD protein levels were assessed by Western blotting, induction of 
sepsis by CLP led to a time-dependent increase in FADD protein expression in aortic 
tissues (Figure 3B). This increase occurred on endothelial cells since FADD protein 
expression was not increased in endothelium-denuded aortic tissues from septic animals. 
For silencing of gene expression of FADD, siRNA oligonucleotides with the following 
sense and antisense sequences were designed: 5’-GCA GUC UUA UUC CUA Att-3’ and 
5’-UUA GGA AUA AGA GGA GUA Ctt-3’ (Matsuda et al., 2009, 2010b). In vivo 
transfection of synthetic siRNAs via tail vein was performed at 10 hours after CLP with 
Lipofectamine RNAiMAX (Invitrogen). We used Opti-MEM I Reduced Serum Medium 
(Invitrogen) to dilute siRNAs and Lipofectamine RNAiMAX before complexing, by which 
50 g of FADD siRNA sequence was usually delivered. Systemic delivery of FADD siRNA 
nearly completely eliminated aortic protein expression of FADD (Figure 3B). We also 
confirmed that the increased levels of FADD mRNA and protein in lungs after CLP 
induction of sepsis were strongly suppressed by systemic application of FADD siRNA but 
not of scrambled siRNA (Matsuda et al., 2009). These findings suggested the successful 
efficacy of systemically administered siRNA for silencing tissue expression of FADD in 
septic mice. 
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Western blots of TNF-R1 and Fas in the membrane fractions (A) and FADD in the total fractions (B) of 
aortic vessels from mice that were subjected to sham-operation (control) and sepsis (10 and 24 hours 
after CLP). -Actin and adaptin- served as loading control. In B, sepsis-induced up-regulation of 
FADD protein expression was eliminated by systemic delivery of FADD siRNA. Note that no increase 
in death receptors and FADD was observed when the endothelium was removed by gently rubbing the 
intimal surface. 
Fig. 3. Endothelium-dependent increases in expression of death receptors and FADD in 
aortic vessels of septic mice. 
3.2 Effect of FADD siRNA on cell apoptosis in sepsis 
To assess whether FADD siRNA treatment has a beneficial effect on sepsis-induced 
apoptotic cell death in lungs, the tissue sections were labeled with an in situ TUNEL assay 
(Figure 4A). Apparently, no TUNEL-positive cells were observed in sham control mice. 
Induction of sepsis by CLP resulted in a striking appearance of TUNEL-positive cells. 
Apoptotic cells were identical morphologically to endothelial cells of capillary vessels in the 
alveolar septa and to epithelial type II cells (Matsuda et al., 2009). In agreement with this 
finding, our recent immunofluorescence studies showed that the cleaved form of caspase-3 
was present in cell types other than CD31-positive endothelial cells in lungs (Takano et al., 
2011). In lungs from CLP mice treated with FADD siRNA, but not with scrambled siRNA, 
TUNEL-positive cells were decreased sharply, providing a protective effect of FADD siRNA 
treatment on pulmonary cell apoptosis mediated by sepsis. 
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Sections of the lung (A) and spleen (B) were prepared from mice that were underwent sham procedure, 
CLP, CLP and FADD siRNA administration, or CLP and scrambled siRNA administration. Tissues 
were harvested 24 hours after surgery. In A, TUNEL-positive apoptotic cells are indicated by arrows. 
Scale bars = 20 m (A) and 200 m (B). 
Fig. 4. Mouse lung and spleen tissue sections showing apoptotic cells by an in situ TUNEL 
assay. 
Physiologic TUNEL-positive cells, morphologically identical to lymphocytes (Matsuda et al., 
2009, 2010a), were sporadically present in the spleen tissues from sham control mice (Figure 
4B). In spleens 24 hours after septic insult, marked apoptosis of follicular lymphocytes were 
observed. Most apoptotic lymphocytes were located in the white pulp of the spleen. 
TUNEL-positive lymphocytes in spleen follicles were greatly reduced when FADD siRNA 
was systemically given after CLP. Administration of scrambled siRNA to septic mice 
showed more frequent TUNEL positivity than no treatment. 
Light microscopic studies of aortic tissue sections from septic mice at 24 hours after CLP 
showed partial detachment of endothelial cells from the basal membrane (Matsuda et al., 
2007, 2010b). When the tissue sections were labeled with an in situ TUNEL assay, a 
significant number of apoptotic endothelial cells was found in aortas of septic mice 
(Matsuda et al., 2007, 2010b). Furthermore, scanning electron microscopic analysis indicated 
that the structure of aortic endothelium displayed a remarkable morphological abnormality: 
most endothelial cells were badly swollen (Figure 5A). Such an endothelial histological 
injury was strikingly prevented by systemic treatment with FADD siRNA but not with 
scrambled siRNA. 
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Mice were underwent sham procedure, CLP, or CLP and FADD siRNA administration. Aortic 
endothelial cells were evaluated by scanning electron microscopy (SEM, A) and by transmission 
electron microscopy (TEM, B) 24 hours after surgry. Septic mice showed anomalous swelling of cells 
(SEM) and autophagy-related vacuolation in the cytoplasm (TEM). These electron-microscopical 
changes were prevented by systemic treatment with FADD siRNA. Scale bars = 2 m. 
Fig. 5. Electron microscopic analysis of mouse aortic endothelial cells. 
3.3 Effect of FADD siRNA on sepsis-induced autophagy in endothelial cells 
A non-apoptotic and non-oncotic type of cell death has been recognized (Clarke, 1990). This 
type of cell death is characterized by the appearance of double- or multi-membrane 
cytoplasmic vesicles engulfing bulk cytoplasm and cytoplasmic organelles, such as 
mitochondria and endoplasmic reticulum, and their delivery to and subsequent degradation 
by the lysosomal system of the same cell (Gozuacik & Kimchi, 2004). This type of cell death 
is referred to as autophagic cell death, but it is still unsettled whether autophagy is the direct 
primary cause of cell death or a compensatory mechanism that tries to rescue a cell from 
dying. In starvation, autophagy provides an internal source of nutrients for energy 
generation, promoting cell survival. Defects in autophagy have been implicated in the 
pathophysiology of cancer and neurodegenerative diseases (Rabinowitz & White, 2010). On 
the other hand, systemic inflammatory response syndrome and multiple organ dysfunction 
syndrome are suggested to be accompanied by increased cell death, including autophagy, in 
the affected organs (Yasuhara et al., 2007). A recent report has shown that LPS induces 
autophagy in human umbilical vein endothelial cells (Meng et al., 2010). Moreover, LPS-
induced systemic inflammation has been demonstrated to exert autophagy of hepatocytes in 
streptozotocin-induced diabetic rats (Hagiwara et al., 2010). 
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Our ultrastructural analysis using transmission electron microscopy indicated the formation 
of autophagy-like vesicles in aortic endothelial cells of CLP septic mice (Figure 5B). 
Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a soluble protein with a 
molecular mass of ~17 kDa that is distributed ubiquitously in mammalian tissues. Cleavage 
of LC3 at the carboxyterminus immediately following synthesis yields the cytosolic LC3-I 
form. LC3-I form is converted to LC3-II during autophagy. Thus, LC3-II is widely used as an 
indicator of autophagy (Kabeya et al., 2000). Western blot analysis revealed significantly 
elevated aortic LC3-II levels in the CLP septic group (Figure 6). Very interestingly, these 
autophagy-related changes were prevented by systemic application of FADD siRNA 
(Figures 5B and 6). 
 
 
Immunoblotting of LC3 usually reveals two bands: the cytosolic form LC3-I and the membrane-bound 
form LC3-II. Sepsis (24 hours after CLP) resulted in a significant conversion of LC3-I to LC3-II. Tracking 
the conversion of LC3-I to LC3-II is indicative of autophagic activity. Systemic administration of FADD 
siRNA prevented this conversion. Summarized data are presented as the mean ± S.E. of five different 
experiments. *P<0.05 vs. sham control. #P<0.05 vs. CLP alone. 
Fig. 6. Immunoblot analysis of LC3 in mouse aortic vessels. 
There are several lines of experimental evidence that apoptosis and autophagy may be 
interconnected in some settings, and in some cases even simultaneously regulated by the 
same trigger resulting in different cellular outcomes (Gozuacik & Kimchi, 2004). Previous 
data supporting the interconnection between the two types of cell death have come from 
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gene expression profiles during steroid-triggered developmental cell death in the Drosophila 
system where several apoptosis-related genes are up-regulated together with autophagy-
related genes (Gorski et al., 2003; Lee et al., 2003). In other cellular settings, autophagy may 
antagonize apoptosis and inhibition of autophagy may increase the sensitivity of the cells to 
apoptotic signals (Gozuacik & Kimchi, 2004). Moreover, apoptosis and autophagy may 
manifest themselves in a mutually exclusive manner. Inhibition of autophasic activity in 
cells may switch responses to death signals from autophagic to apoptotic cell death 
(Gozuacik & Kimchi, 2004). In addition, there are numerous reports showing a direct 
physical interaction between autophagy-inducing proteins and proteins involved in 
apoptosis, especially anti-apoptotic Bcl-2 family members (Liang et al., 1998; Vande Velde et 
al., 2000; Yanagisawa et al., 2003). 
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Mortality was monitored 4 times daily, and survival time was recorded for 7 days. Systemic delivery of 
FADD siRNA, but not scrambled siRNA, resulted in a significant survival benefit. Percentage survival 
of mice after CLP is plotted. Ten mice for each group underwent CLP. 
Fig. 7. Kaplan-Meier survival curves after CLP in mice given FADD siRNA. 
3.4 Effect of FADD siRNA on animal survival after CLP 
To evaluate the impact of FADD siRNA on survival benefit in sepsis, we examined mortality 
in mice subjected to CLP (Figure 7). After CLP, mice exhibited signs of sepsis. Thus, they 
showed lack of interest in their environment, displayed piloerection, and had crusty 
exudates around their eyes. Finally, all animals subjected to CLP without treatment died 
within 2 days. Treatment of CLP mice with scrambled siRNA was without effect on 
survival. However, when FADD siRNA was administered to CLP mice, its survival 
advantage was very striking (P<0.0001; Log rank test). Even at the end of 7 days, a greater 
proportion of the animals given FADD siRNA survived CLP with 80%. 
4. Conclusions 
Despite recent advances in antibiotics and critical care therapy, sepsis treatment remains 
clinical conundrum, and its prognosis is still poor, especially when septic shock and/or 
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multiple organ failure develop. Although a host of promising candidates for therapeutic 
intervention in sepsis have been propelled, almost all of these trials have failed to 
demonstrate a mortality benefit for patients suffering from sepsis. Ongoing research into 
this highly lethal disorder has shown that apoptosis is fully associated with an unfavorable 
outcome of sepsis and its inhibition may provide useful therapies for treatment of sepsis. 
Here we propose that FADD siRNA therapy may offer a unique alternative sepsis treatment 
to shorten the apoptotic arm of sepsis. This therapy salvaged immune effector cells, vascular 
endothelial cells, and parenchyma cells from apoptosis, which would arrest the 
development of complications arising from sepsis, including multiple organ failure, and 
ultimately have a beneficial impact on septic mortality. While appreciating that additional 
work is required to optimize preclinical and possibly clinical application, treatment with 
FADD siRNA will hopefully provide novel potential usefulness for gene therapy that could 
improve the survival of critically ill septic patients. 
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